MikeTrendsTrends right now

search

data science

Trends

  1. 1

    SELLAS Life Sciences announced its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia has reached its 80th event, a key milestone that brings the study closer to its data analysis stage. Investors are watching the biotech stock closely as the trial progresses toward potential results that could shape the company's regulatory prospects.

Repos